Search

Search Constraints

You searched for: Author/Creator Codreanu, Catalin

Search Results

2. 2016 update of the EULAR recommendations for the management of early arthritis. Issue 6 (15th December 2016)

4. AB0752 DRUG RETENTION AND REMISSION RATES IN 14, 261 BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE – RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION. (June 2019)

5. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries. Issue 2 (13th September 2022)

6. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. Issue 2 (5th November 2018)

7. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Issue 9 (5th May 2018)

8. Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. (17th June 2019)

9. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. Issue 3 (19th September 2020)

10. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Issue 11 (3rd June 2021)